BRPI0819783A2 - Subfamília simiana e adenovírus sadv-39, -25.2, -26, -30, -37 e -38 e usos dos mesmos. - Google Patents

Subfamília simiana e adenovírus sadv-39, -25.2, -26, -30, -37 e -38 e usos dos mesmos.

Info

Publication number
BRPI0819783A2
BRPI0819783A2 BRPI0819783-0A BRPI0819783A BRPI0819783A2 BR PI0819783 A2 BRPI0819783 A2 BR PI0819783A2 BR PI0819783 A BRPI0819783 A BR PI0819783A BR PI0819783 A2 BRPI0819783 A2 BR PI0819783A2
Authority
BR
Brazil
Prior art keywords
adenovirus sadv
subfamily
simian
simian subfamily
sadv
Prior art date
Application number
BRPI0819783-0A
Other languages
English (en)
Inventor
Soumitra Roy
James M Wilson
Luc H Vandenberghe
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of BRPI0819783A2 publication Critical patent/BRPI0819783A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI0819783-0A 2007-11-28 2008-11-24 Subfamília simiana e adenovírus sadv-39, -25.2, -26, -30, -37 e -38 e usos dos mesmos. BRPI0819783A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US449907P 2007-11-28 2007-11-28
US454107P 2007-11-28 2007-11-28
US446407P 2007-11-28 2007-11-28
US446107P 2007-11-28 2007-11-28
US453207P 2007-11-28 2007-11-28
US450707P 2007-11-28 2007-11-28
PCT/US2008/013066 WO2009073104A2 (en) 2007-11-28 2008-11-24 Simian e adenoviruses sadv-39, -25. 2, -26, -30, -37, and -38

Publications (1)

Publication Number Publication Date
BRPI0819783A2 true BRPI0819783A2 (pt) 2015-06-23

Family

ID=40380705

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819783-0A BRPI0819783A2 (pt) 2007-11-28 2008-11-24 Subfamília simiana e adenovírus sadv-39, -25.2, -26, -30, -37 e -38 e usos dos mesmos.

Country Status (20)

Country Link
US (3) US8685387B2 (pt)
EP (2) EP3128010A1 (pt)
JP (3) JP5740158B2 (pt)
KR (3) KR101614364B1 (pt)
CN (1) CN101883858B (pt)
AU (1) AU2008331906B2 (pt)
BR (1) BRPI0819783A2 (pt)
CA (2) CA2706258C (pt)
CY (1) CY1118351T1 (pt)
DK (1) DK2220241T3 (pt)
ES (1) ES2607029T3 (pt)
HR (1) HRP20161573T1 (pt)
HU (1) HUE032142T2 (pt)
LT (1) LT2220241T (pt)
MX (2) MX347246B (pt)
PL (1) PL2220241T3 (pt)
PT (1) PT2220241T (pt)
SG (1) SG10201604001XA (pt)
SI (1) SI2220241T1 (pt)
WO (1) WO2009073104A2 (pt)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170395T1 (hr) 2007-11-28 2017-05-05 The Trustees Of The University Of Pennsylvania Podporodice adenovirusa b majmuna sadv-28, 27,-29,-32,-33, i -35 i njihove primjene
EP3128010A1 (en) * 2007-11-28 2017-02-08 The Trustees Of The University Of Pennsylvania Simian subfamily e adenoviruses sadv-30 and uses thereof
CN102131920B (zh) 2007-11-28 2013-11-06 宾夕法尼亚大学托管会 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用
EP2325298B1 (en) * 2008-03-04 2016-10-05 The Trustees Of The University Of Pennsylvania SIMIAN ADENOVIRUSES SAdV-36, -42.1, -42.2, AND -44 AND USES THEREOF
ES2552688T3 (es) 2008-10-31 2015-12-01 The Trustees Of The University Of Pennsylvania Adenovirus de simio con proteínas de la cápside hexónica de SAdV-46 y usos del mismo
AU2010209938A1 (en) * 2009-02-02 2011-08-25 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CA2762203A1 (en) 2009-05-29 2010-12-02 Soumitra Roy Simian adenovirus 41 and uses thereof
EA201270607A1 (ru) 2009-11-09 2012-09-28 Генвек, Инк. Аденовирус обезьян и способы его использования
WO2011057254A2 (en) * 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
AU2011332025B2 (en) * 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
EP2651439B1 (en) * 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
US9267112B2 (en) 2011-05-10 2016-02-23 The Regents Of The University Of California Adenovirus isolated from Titi Monkeys
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
MX358019B (es) 2012-05-18 2018-08-02 Univ Pennsylvania Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos.
PL2880160T3 (pl) * 2012-08-03 2019-03-29 Cedars-Sinai Medical Center Izolowanie wzmacniających transport mutantów białka dostarczającego lek
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
EP3198009B1 (en) 2014-09-24 2021-09-08 Salk Institute for Biological Studies Oncolytic tumor viruses and methods of use
WO2016057387A1 (en) 2014-10-06 2016-04-14 The Trustees Of The University Of Pennsylvania Compositions and methods for isolation of circulating tumor cells (ctc)
CN112553229A (zh) 2014-11-05 2021-03-26 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
EP3256156B1 (en) 2015-02-13 2025-02-12 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
JP6983665B2 (ja) * 2015-06-12 2021-12-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アデノウイルスポリヌクレオチド及びポリペプチド
AU2016362477A1 (en) 2015-12-02 2018-06-14 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
BR112018073472A2 (pt) 2016-05-18 2019-08-27 Voyager Therapeutics, Inc. composições e métodos de tratamento da doença de huntington
AU2017313917B2 (en) 2016-08-18 2023-12-21 The Regents Of The University Of California CRISPR-Cas genome engineering via a modular AAV delivery system
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
JP7794421B2 (ja) 2016-12-12 2026-01-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
CN111108198A (zh) 2017-05-05 2020-05-05 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导系统
WO2019028306A2 (en) 2017-08-03 2019-02-07 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
KR20200077559A (ko) 2017-10-31 2020-06-30 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 및 이의 용도
EP3704138A1 (en) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
JP7229239B2 (ja) 2017-10-31 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルスベクター及びその用途
JP7438943B2 (ja) 2017-10-31 2024-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルス及びその用途
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
AU2019268330A1 (en) 2018-05-15 2020-11-26 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease
US12060567B2 (en) 2018-06-13 2024-08-13 Voyager Therapeutics, Inc. Engineered untranslated regions (UTR) for AAV production
AU2019304569B2 (en) 2018-07-17 2023-07-06 Helixmith Co., Ltd Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
MX2021000810A (es) 2018-07-24 2021-04-28 Voyager Therapeutics Inc Sistemas y metodos para producir formulaciones de terapia genetica.
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
WO2020072844A1 (en) 2018-10-05 2020-04-09 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding aav production proteins
CN113166781A (zh) 2018-10-15 2021-07-23 沃雅戈治疗公司 在杆状病毒/Sf9系统中大规模生产rAAV的表达载体
KR20210130158A (ko) 2019-01-31 2021-10-29 오레곤 헬스 앤드 사이언스 유니버시티 Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
EP4178605A1 (en) 2020-07-13 2023-05-17 Transgene Treatment of immune depression
EP4284335A1 (en) 2021-02-01 2023-12-06 RegenxBio Inc. Gene therapy for neuronal ceroid lipofuscinoses
WO2022218997A1 (en) 2021-04-12 2022-10-20 Centre National De La Recherche Scientifique (Cnrs) Novel universal vaccine presenting system
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
US20250276095A1 (en) 2024-03-04 2025-09-04 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
WO2025226842A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Expression control by drg-expressed mirnas
WO2025226841A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Gene therapy approach for treating disorders associated with tnnt2
WO2026011008A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Expression control by skeletal muscle-expressed mirnas
WO2026011009A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Compositions and methods for muscle disorders
WO2026030242A1 (en) 2024-07-29 2026-02-05 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy
WO2026030244A1 (en) 2024-07-30 2026-02-05 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a
WO2026050402A1 (en) 2024-08-29 2026-03-05 Kate Therapeutics, Inc. Liver de-targeted muscle tropic capsids

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1364343A1 (ru) 1984-07-13 1988-01-07 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Способ получени человеческого лейкоцитарного интерферона альфа-2
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4732683A (en) 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
JPH10507758A (ja) 1994-10-19 1998-07-28 ジェネティック セラピー，インコーポレイテッド アデノウイルスおよび免疫抑制剤同時反復投与を伴う遺伝子治療
PT787200E (pt) 1994-10-28 2005-08-31 Univ Pennsylvania Adenovirus melhorado e metodos para a sua utilizacao
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
EP1015619A1 (en) 1997-09-19 2000-07-05 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
AU1822499A (en) * 1997-12-12 1999-06-28 Saint Louis University Ctip, a novel protein that interacts with ctbp and uses therefor
DE69922934T2 (de) 1998-03-20 2005-12-08 The Trustees Of The University Of Pennsylvania Zusammensetzungen und Verfahren zur helfer-freien Herstellung von rekombinanten Adeno-assoziierten Viren
WO2000011140A1 (en) 1998-08-20 2000-03-02 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
WO2001054719A2 (en) 2000-01-31 2001-08-02 Smithkline Beecham Biologicals S.A. Vaccine for the prophylactic or therapeutic immunization against hiv
AU2001234981A1 (en) 2000-02-09 2001-08-20 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
ATE530672T1 (de) 2001-06-22 2011-11-15 Univ Pennsylvania Rekombinante adenoviren mit affen-adenovirus proteinen und verwendung davon.
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
JP4754480B2 (ja) * 2003-06-20 2011-08-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア キメラアデノウイルスの作成法およびそのようなキメラアデノウイルスの使用
DK1711518T3 (da) * 2004-01-23 2010-04-06 Angeletti P Ist Richerche Bio Vaccinebærere for chimpanse-adenovirus
US20080004236A1 (en) 2004-02-06 2008-01-03 Comper Wayne D High Dose, Short Interval Use of Sulfated Polysaccharides for Treatment of Infections
ES2371175T3 (es) 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
AU2006212012B2 (en) 2005-02-12 2011-10-13 Swedish Orphan Biovitrum International Ab Methods and uses of antibodies in the purification of interferon
BRPI0608798A2 (pt) * 2005-05-12 2011-03-15 Glaxo Group Ltd vetor de adenovìrus, composição imunogênica, uso de um vetor de adenovìrus, método para preparar um vetor, uso de um vetor de vìrus e um carreador ou adjuvante farmaceuticamente aceitável, e, proteìna de fusão
DE602007004470D1 (de) 2006-04-28 2010-03-11 Univ Pennsylvania Modifiziertes adenovirus-hexon-protein und anwendungen davon
EP3128010A1 (en) 2007-11-28 2017-02-08 The Trustees Of The University Of Pennsylvania Simian subfamily e adenoviruses sadv-30 and uses thereof
CN102131920B (zh) 2007-11-28 2013-11-06 宾夕法尼亚大学托管会 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用
HRP20170395T1 (hr) * 2007-11-28 2017-05-05 The Trustees Of The University Of Pennsylvania Podporodice adenovirusa b majmuna sadv-28, 27,-29,-32,-33, i -35 i njihove primjene
EP2325298B1 (en) 2008-03-04 2016-10-05 The Trustees Of The University Of Pennsylvania SIMIAN ADENOVIRUSES SAdV-36, -42.1, -42.2, AND -44 AND USES THEREOF
US9603035B2 (en) 2011-10-13 2017-03-21 Telefonaktiebolaget L M Ericsson Method and node related to channel estimation

Also Published As

Publication number Publication date
JP2015083006A (ja) 2015-04-30
KR20100109915A (ko) 2010-10-11
AU2008331906B2 (en) 2014-03-06
PT2220241T (pt) 2016-12-26
KR101761691B1 (ko) 2017-07-26
SI2220241T1 (sl) 2017-02-28
CA2964396A1 (en) 2009-06-11
MX347246B (es) 2017-04-19
AU2008331906A1 (en) 2009-06-11
DK2220241T3 (en) 2017-01-09
WO2009073104A2 (en) 2009-06-11
MX2010005858A (es) 2010-06-11
PL2220241T3 (pl) 2017-06-30
US20160244783A1 (en) 2016-08-25
CY1118351T1 (el) 2017-06-28
HUE032142T2 (en) 2017-08-28
KR101614364B1 (ko) 2016-04-22
CA2706258C (en) 2017-06-06
WO2009073104A8 (en) 2016-03-31
LT2220241T (lt) 2016-12-12
CA2706258A1 (en) 2009-06-11
KR20160118370A (ko) 2016-10-11
US20140155476A1 (en) 2014-06-05
JP2016195595A (ja) 2016-11-24
HRP20161573T1 (hr) 2017-02-10
EP2220241B1 (en) 2016-09-14
KR101662574B1 (ko) 2016-10-05
JP5740158B2 (ja) 2015-06-24
US20100247490A1 (en) 2010-09-30
EP3128010A1 (en) 2017-02-08
ES2607029T3 (es) 2017-03-28
KR20150108945A (ko) 2015-09-30
JP6224769B2 (ja) 2017-11-01
SG10201604001XA (en) 2016-07-28
CN101883858B (zh) 2015-07-22
JP2011522513A (ja) 2011-08-04
EP2220241A2 (en) 2010-08-25
US8685387B2 (en) 2014-04-01
CN101883858A (zh) 2010-11-10
US9359618B2 (en) 2016-06-07
WO2009073104A3 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
BRPI0819783A2 (pt) Subfamília simiana e adenovírus sadv-39, -25.2, -26, -30, -37 e -38 e usos dos mesmos.
NO2022027I1 (no) Combination of daunorubicin and cytarabine
FR20C1066I2 (fr) Pièges à gdf pour l'utilisation dans le traitment de l'anémie
FI20050450L (fi) Keskipakopumppu ja sen juoksupyörä
BRPI0807495A2 (pt) Adjuvantes e métodos de emrpego dos mesmos
ATE526916T1 (de) Beleuchtete infusions- und inzisionskanüle
EP1976905A4 (en) MIXTURES OF BIOPOLYMERS WITH ACRYLIC POLYMERS
EP1605988A4 (en) IMPROVED CANNULA
DK3176159T3 (da) 4-phenyl-6-(2,2,2-trifluor-1-phenylethoxy)pyrimidin-baserede forbindelser og fremgangsmåder til anvendelse deraf
BRPI0818511A2 (pt) Novos compostos de miméticos de giro reverso e uso dos mesmos (1)
EP2128132A4 (en) OXIMESTER CONNECTION AND PHOTOPOLYMERIZATION INITIATOR WITH THE CONNECTION
PT1849470T (pt) Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase
FR2939799B1 (fr) Composition cosmetique comprenant des oligoglucuronanes acetyles.
BRPI0812335A2 (pt) Polimorfismos de milho e métodos de genotipagem.
EP2073738A4 (en) ABLATION CATHETER DEVICE WITH ONE OR MORE ELECTRODES
PT2963031T (pt) Pró-fármacos de tetrahidrocanabinol, composições compreendendo pró-fármacos de tetrahidrocanabinol e métodos de utilização dos mesmos
BRPI0817269A2 (pt) Análogos de azacitidina e usos dos mesmos
DE602007000091D1 (de) Radialventilator
EP2196936A4 (en) SAFE START-UP END UNIT, SAFE START-UP PROCEDURE, SAFE STARTER PROGRAM, RECORDING MEDIA AND INTEGRATED CIRCUIT
EP2171096A4 (en) CARBOXYL REPAIRS-1-POLYMORPHISMS AND METHOD FOR THEIR USE
BRPI0807907A2 (pt) co-cristais e composições farmacêuticas compreendendo os mesmos.
EP1974685A4 (en) DWELL MEDICAL DEVICE
BRPI0907624A2 (pt) tratamento e prevenção de doenças cardíacas usando duas ou mais isoformas do fator de crescimento de hepatócito
BRPI0715342A2 (pt) Derivados de 6-carboxi-normorfinano, síntese e usos dos mesmos
BRPI0907572A2 (pt) Derivados de fluorglicosídeos aromáticos, fármacos compreendendo os referidos compostos e uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion)
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 11A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2541 DE 17-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.